Intended for healthcare professionals

Letters WHO analgesic ladder

WHO analgesic ladder gone astray: wider implications

BMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i589 (Published 04 February 2016) Cite this as: BMJ 2016;352:i589
  1. Michael H Basler, consultant in pain management,
  2. Paul W Keeley, consultant palliative physician
  1. Glasgow Royal Infirmary, Glasgow G4 0SF, UK
  1. Michael.Basler{at}ggc.scot.nhs.uk

In the past the medical use of opioids has depended on many factors.1 Opioids are essential drugs that need to be safeguarded by appropriate use.2 Ballantyne and colleagues3 point out that the WHO analgesic ladder was developed for the treatment of terminal cancer and that the wider interpretation of this treatment pathway has led to problems. Many guidelines rely on the WHO ladder approach for the blanket treatment of cancer pain.4 Advances in treatment and increasing cancer survival have led to a rise in chronic complications that can cause serious pain.5

In our experience, the widespread use of the WHO ladder for cancer pain has led to serious opioid based problems in a small group of patients. Moreover, palliative care doctors have extended their role in the management of multiple chronic conditions that can be associated with pain.6 Opioids are the cornerstone of their therapeutic armamentarium. Lessons learnt by both pain clinicians and GPs about the WHO ladder need to be disseminated more widely. This should include oncologists and palliative care doctors as well as the wider medical fraternity. The medical duty of all doctors is to prevent hurt and stop harm, especially when the harm is iatrogenic.

Footnotes

  • Competing interests: No competing interests

References

View Abstract

Log in

Log in through your institution

Subscribe

* For online subscription